Doctor Discussion Guide
Doctor Discussion Guide
 Doctor Discussion Guide Be prepared to talk with a doctor about CPP and your child. Take our Doctor Discussion Guide with you to your pediatrician visit to help you get the answers you need.
Parent Survey
Growth Comparison Tool
Parent Survey How does your child compare to other children with central precocious puberty (CPP)? Take our interactive Parent Survey and get a better understanding of the condition.
Glossary
Log In
Filled with medical definitions commonly related to CPP, this glossary was created to help you understand your child's diagnosis and treatment. If you have any further questions, please ask your child's doctor.

ADRENAL

pertaining to either of two adrenal glands located just above the kidneys.

ADRENAL GLAND

either of two small glands, one at the upper end of each kidney.

BENIGN

not malignant (not cancerous).

COMPUTERIZED AXIAL TOMOGRAPHY (CAT) SCAN

a painless process in which a computer generates cross-section views of a patient's anatomy. It can identify normal and abnormal structures, and it can be used to guide procedures.

CENTRAL PRECOCIOUS PUBERTY

a condition that causes children to enter puberty too soon, resulting in accelerated bone growth, and the development of secondary sex characteristics.

ENDOCRINE

applies to organs and structures that release their products into the blood or lymph, and to hormones that exert specific effects on other organs.

ENDOCRINOLOGY

medical discipline dealing with disorders of the endocrine glands and hormones regulating bodily functions.

FERTILITY

ability to have children.

GnRH

gonadotropin-releasing hormone.

GnRH AGONIST

a synthetic version of naturally occuring GnRH (gonadotropin-releasing hormone).

GLAND

a group of cells that secrete a substance for use in the body
(eg, pituitary gland).

GONAD

a reproductive gland (ie, an ovary or testis).

GONADOTROPIC

acting on or stimulating the gonads.

HORMONE

substance secreted by cells or tissue that functions in the regulation of physiological activities.

HYPOTHALAMUS

the area of the brain that controls body temperature, sleep, hunger and thirst, and the development of secondary sex characteristics.

MAGNETIC RESONANCE IMAGING (MRI)

a method of visualizing soft tissues of the body by applying an external magnetic field.

MALIGNANT

tending to be severe and become progressively worse; also a cancerous tumor.

OVARIES

the female sex glands. The ovaries produce eggs and are the body's main source of female hormones. These hormones control the development of female body characteristics, such as the breasts, body shape, and body hair. They also regulate the menstrual cycle and pregnancy.

PITUITARY

the main endocrine gland, which produces hormones that control other glands and many body functions.

PUBERTY

adolescence, the period in which the human body first becomes capable of reproduction.

SCROTUM

a pouch of skin that contains the testes, epididymides, and lower portions of the spermatic cords.

SECONDARY SEX CHARACTERISTICS

those characteristics specific to the male or female but not directly involved in reproduction.

SIDE EFFECT

an unintended effect of a drug.

SYMPTOM

subjective feeling that indicates the presence of a physical disorder.

TESTICLES

the male sex glands, located behind the penis in a pouch of skin called the scrotum. The testicles produce and store sperm and are also the body's main source of male hormones, such as testosterone. These hormones control the development of the reproductive organs and other male characteristics, such as body and facial hair, low voice, and wide shoulders. Also known as testes and male gonads.

TUMOR

an abnormal mass of tissue. Tumors can be benign or malignant.

ULTRASOUND

a diagnostic procedure that uses sound waves to record pictures of internal organs.

See below for important safety and other information on Lupron Depot-PED.
All photos are of models and not of users of Lupron Depot-PED or persons suffering symptoms described.
    

Important Safety and Other Information:

Lupron Depot-PED (7.5 mg, 11.25 mg, and 15 mg) is used for the treatment of central precocious puberty. In clinical studies, the most frequent adverse event related to therapy with Lupron Depot-PED was an injection site reaction, seen in 5% of children in the combined studies. The recommended starting dose of Lupron Depot-PED is 0.3 mg/kg/4 weeks (minimum 7.5 mg). Inadequate dosing may result in poor control of the pubertal process.

For further information about Lupron Depot-PED, please see the complete Prescribing Information, as well as the
Patient Product Information.